New Huntington's drug shows promise in Mid-Stage trial
NCT ID NCT05358717
Summary
This study tested an investigational drug called PTC518 in people with Huntington's disease to see if it was safe and if it could lower the harmful protein linked to the disease. 159 participants received either the drug or a placebo for up to a year. The main goals were to check for side effects and measure changes in the disease-related protein in the blood and spinal fluid.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUNTINGTON DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brain and Spine Institute Paris
Paris, 75013, France
-
Cardiff University Schools of Medicine and Biosciences
Cardiff, CF10 3AX, United Kingdom
-
Centre Hospitalier Universitaire d'Angers
Angers, 49100, France
-
Charite University Medicine Berlin
Berlin, 10117, Germany
-
George-Huntington-Institut
Münster, 48149, Germany
-
Hospital Ramón y Cajal
Madrid, 28034, Spain
-
Hospital Universitario Burgos
Burgos, 90550, Spain
-
Hospital Universitario Cruces
Barakaldo, 48903, Spain
-
Hospital de la Santa Creu I Sant Pau
Barcelona, 8025, Spain
-
Hôpital Universitaire de Marseille Hôpital de la Timone
Marseille, 13385, France
-
IRCCS Carlo Besta Neurological Institutte
Milan, 20133, Italy
-
IRCCS Casa Sollievo della Sofferenza Research Hospital
San Giovanni Rotondo, 71013, Italy
-
Irccs Istituto Delle Scienze Neurologiche Di Bologna Uoc Clinica Neurologica
Bologna, 40139, Italy
-
Leiden University Medical Center
Leiden, 2333 ZA, Netherlands
-
Manchester University NHS Foundation Trust
Manchester, M13 9WL, United Kingdom
-
Medical University Innsbruck
Innsbruck, 6020, Austria
-
Monash Health
Clayton, 3168, Australia
-
Ruhr-Univ. Bochum St. Joseph-Hospital
Bochum, 44791, Germany
-
The Barbery National Centre for Mental Health
Birmingham, B15 2FG, United Kingdom
-
The Ottawa Hospital, Parkinson's and Movement Disorders Clinic
Ottawa, K1Y 4E9, Canada
-
The University of Texas Health Science Center at Houston; McGovern Medical School
Houston, Texas, 77030, United States
-
UCL Queen Square Institute of Neurology National Hospital for Neurology and Neurosurgery
London, WC1N 3BG, United Kingdom
-
Ulm University, UKU, Dep. of Neurology
Ulm, 89081, Germany
-
University of California, San Diego
La Jolla, California, 92037, United States
-
University of Otago, New Zealand Brain Research Institute
Christchurch, 8011, New Zealand
-
University of Washington Department of Neurology
Seattle, Washington, 98195, United States
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37212, United States
-
Westmead Hospital
Sydney, 2145, Australia
Conditions
Explore the condition pages connected to this study.